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A B S T R A C T
Heart failure remains a major public-health problem with an increase in the number of patients worsening from
this disease. Despite current medical therapy, the condition still has a poor prognosis. Heart failure is complex
but mitochondrial dysfunction seems to be an important target to improve cardiac function directly.
Our goal was to analyze the effects of MitoQ (100 µM in drinking water) on the development and progression
of heart failure induced by pressure overload after 14 weeks. The main findings are that pressure overload-
induced heart failure in rats decreased cardiac function in vivo that was not altered by MitoQ. However, we
observed a reduction in right ventricular hypertrophy and lung congestion in heart failure animals treated with
MitoQ. Heart failure also decreased total mitochondrial protein content, mitochondrial membrane potential in
the intermyofibrillar mitochondria. MitoQ restored membrane potential in IFM but did not restore mitochondrial
protein content. These alterations are associated with the impairment of basal and stimulated mitochondrial
respiration in IFM and SSM induced by heart failure. Moreover, MitoQ restored mitochondrial respiration in
heart failure induced by pressure overload. We also detected higher levels of hydrogen peroxide production in
heart failure and MitoQ restored the increase in ROS production. MitoQ was also able to improve mitochondrial
calcium retention capacity, mainly in the SSM whereas in the IFM we observed a small alteration. In summary,
MitoQ improves mitochondrial dysfunction in heart failure induced by pressure overload, by decreasing hy-
drogen peroxide formation, improving mitochondrial respiration and improving mPTP opening.
1. Introduction
Despite diagnosis and treatment, heart failure remains a major
clinical problem and a huge economic burden on the health care
system. The incidence and costs are projected to double in the next
twenty years. The disease is highly prevalent in elderly patients and is
associated with high mortality rates within five years of diagnosis de-
spite current optimal medical therapy. Current medical therapy can
prevent new onset and slow the progression once heart failure is es-
tablished but prognosis is still poor even for most favorable treated
patients, and new therapeutic approaches are needed. Heart failure
rehospitalizations rates remain high (35%) within 90 days after dis-
charge and this event has not changed over the last 15 years [1–5].
Commonly prescribed therapies although beneficial in improving
some symptoms often do not approach the underlying causes of pro-
gressive left ventricular dysfunction presented in heart failure [6].
Left ventricular dysfunction is accompanied by derangements in
myocardial fuel metabolism and bioenergetics that contribute to the
development and progression of the disease. The energy supply must
match the energy demand in the adult heart due to its high requirement
of energy to sustain contractile function. In the adult heart, almost all
energy production comes from mitochondrial oxidative phosphoryla-
tion continually generated by oxidation of carbon fuels [7–11].
Growing evidence provides information that alterations in mitochon-
drial ATP production are causally linked to the development of heart
failure. Notably, it has been shown that alterations in fatty acid oxi-
dation and oxidative phosphorylation can cause cardiomyopathy in
humans and decreased levels of phosphocreatine accelerates the decline
during the transition from left ventricular hypertrophy to heart failure
[12–15].
In addition, studies in animals and humans have revealed repro-
gramming of myocardial fuel utilization in the failing heart: a shift from
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the fatty acid oxidation (FAO) to increased reliance on glucose utili-
zation. The mechanisms through which the failing heart shifts substrate
utilization are still poorly understood.
Moreover, mitochondria are recognized as the main source of re-
active oxygen species (ROS) within the cell. ROS production is usually
low under physiological conditions, however, when pathological ROS
production outpaces endogenous scavenging capacity; it can alter
proteins and lipid function, triggering cell death, which typically occurs
in heart failure, therefore, decreasing mitochondrial quality control and
energy supply [16].
To decrease mitochondrial oxidative damage, many mitochondria-
targeted antioxidants have been developed in the last few years and a
promising mitochondrial antioxidant that has emerged is MitoQ, which
consists of a quinone moiety linked to a triphenylphosphonium moiety
by a 10-carbon alkyl chain [17].
MitoQ has been shown to protect against oxidative damage in many
animal models of pathology, including cardiac ischemia–reperfusion
(IR) injury [18], hypertension [19] but the effects on the development
of heart failure remains understood. Therefore, our goal was to analyze
the effects of MitoQ on the development and progression of heart
failure induced by pressure overload.
2. Material and methods
2.1. Experimental design and aortic constriction surgery
The animal protocol was conducted according to the Guideline for
the Care and Use of Laboratory Animals (NIH publication 85–23) and
was approved by the University of Maryland School of Medicine
Institutional Animal Care and Use Committee (Protocol number
1009011).
Animals were anesthetized with 2.5% isoflurane in oxygen, in-
tubated and ventilated. A partial median sternotomy was performed
and the thymus resected. After dissection of the aortic arch, a tantalum
clip (.45 mm internal diameter-Hemoclip) was placed on the aorta be-
tween the brachiocephalic trunk and the left common carotid artery.
The sternotomy was closed with interrupted sutures and the skin closed
with running sutures. After their vital signs were reestablished, rats
were extubated. Rats were kept in 100% oxygen and on warming pads
during the surgery and recovery periods. Age-matched Sham-operated
animals underwent the same procedure without clip application. Three
days after surgery, the animals were assigned to receive MitoQ (100 µM
in drinking water).
2.1.1. Echocardiography
Cardiac function was assessed using a Vevo 2100 High-Resolution
Imaging Systems (Visual Sonics) with a 15-MHz linear array transducer
(MS200) at 13 weeks of treatment as previously described [20]. Rats
were anesthetized with 2.5% isoflurane in oxygen, shaved and placed
on a warming pad. Two-dimensional cine loops and guided M-mode
frames were recorded from the parasternal short and long axes. At the
end of the study, all data were analyzed offline with software resident
on the ultrasound system, and calculations were made to determine left
ventricular volumes. Ejection fraction was calculated as: (end-diastolic
diameter __ end-systolic diameter)/end-diastolic diameter. Relative wall
thickness was calculated as the sum of the posterior and anterior wall
thickness at end diastole divided by the end diastolic diameter. Mean
wall thickness was taken as the average of the posterior and anterior
wall thickness at end diastole. All calculations were made from para-
sternal short axis measurements.
2.1.2. Tissue harvest
After 14 weeks of treatment, the animals were anaesthetized with
5.0% isoflurane between 3 and 6 h after initiation of the light phase
while given free access to food. The thorax was opened and blood was
collected from the left ventricle and immediately placed on ice tubes
containing or not EDTA, and centrifuged at 1500 g for 15min at 4 °C to
obtain serum and plasma, respectively. The heart was removed, and
three sections of the left ventricle free wall were taken for biochemical
analysis and stored at −80 °C, and the remainder was used for mi-
tochondrial isolation as described below.
2.1.3. Mitochondrial isolation
Subsarcolemmal mitochondria (SSM) and interfibrillar mitochon-
dria (IFM) were isolated as previously described [20–22]. Briefly, the
LV was rinsed in ice cold Chappel-Perry buffer (100mM KCl, 50mM
MOPS, 5mM MgSO4, 1mM ATP, 1mM EGTA, 2mg/mL BSA), blotted
dry and then weighed. The ventricles were minced and homogenized in
1:10 (wt/vol) ice cold Chappel-Perry buffer. The homogenates were
centrifuged at 580×g for 10min. The supernatant containing SSM was
extracted and centrifuged again at 5000×g to isolate SSM. The re-
maining pellet from the 580×g spin was resuspended in KCl-MOPS-
EGTA buffer containing 100mM KCl, 50mM MOPS, and 0.5 mM EGTA
at pH 7.4, and treated with trypsin (5mg/g) for 10min at 4 °C. The
samples were incubated with Chappel-Perry buffer (albumin 2mg/mL)
to inhibit trypsin and spun down at 580×g for 10min. The IFM-con-
taining supernatant was spun down at 5000×g for 10min. The pellets
were washed in ice cold Chappel-Perry buffer and spun down at
5000×g for 10min and washed in KME (100mM KCl, 50mM MOPS,
and 0.5 mM EGTA at pH 7.4) and then resuspended in KME. The con-
centration of mitochondrial protein was measured by the Lowry
method using bovine serum albumin as standard.
2.1.4. Mitochondrial respiration
Mitochondrial respiration was assessed in both IFM and SSM as
described previously [21,23]. Isolated mitochondria (0.5 mg/mL) were
respired in respiration buffer containing 100mM KCl, 50mM MOPS,
5mM KH2PO4, 1mM EGTA and 1mg/mL BSA/Fraction V, using a
polarographic oxygen sensing systems for measurements of dissolved
oxygen consumption in liquid suspension (Qubit System, Kingston, ON,
Canada). States 3 and 4 were measured with glutamate + malate (10
and 5mM, respectively), palmitoylcarnitine (40 μM) and Succinate
(20mM) with rotenone (7.5 μM) was used to assess respiration through
Complex II of the ETC exclusively. State 3 respiration (ADP-stimulated)
was measured in the presence of 200 μM ADP. State 4 respiration (ADP-
limited) was assessed after ADP consumption. Respiratory Control
Ratio, the ratio of State 3 to State 4 was calculated to assess the control
of oxygen consumption by phosphorylation. The ratio of ADP added in
the chamber to the total amount of oxygen consumed in state 3 (ADP:O
ratio) was calculated as an index of the efficiency of oxidative phos-
phorylation.
2.1.5. Mitochondrial membrane potential (ΔΨm), size and complexity
Membrane potential, size and internal complexity were determined
by flow cytometry analyses using Facscan (Becton Dickinson) as pre-
viously described [23]. Distinct mitochondrial subpopulations, IFM and
SSM were incubated with the ratiometric dye 5,5′,6,6′-tetrachloro-
1,1′,3,3′-tetraethylbenzimidazol carbocyanine iodide (JC-1; Invitrogen)
for 15min at 37 °C (final concentration 300 nM), which is a lipophilic
cation that enters selectively into mitochondria, or MitoTracker Deep
Red 633 (Invitrogen), which passively diffuses into intact mitochondria
due to membrane potential and selectively stain intact mitochondria.
Each individual parameter (gating, size, and complexity) was per-
formed using specific light sources, detectors and 100,000 gated events
were analyzed per sample. Measurements were performed on freshly
isolated mitochondria and values are expressed as the mean orange
fluorescence divided by the mean green fluorescence for membrane
potential analyses (JC-1). For size and internal complexity analyses
(MitoTracker), geometric mean representing FSC (forward scatter-
logarithmic scale) was used as an indicator of size, whereas values from
SSC (side scatter-logarithmic scale) were used to indicate complexity.
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2.1.6. Mitochondrial permeability transition pore (MPTP) opening assay
MPTP opening in SSM and IFM was performed as previously de-
scribed [20,24]. Brief, mitochondria (500 µg) were resuspended in
2.0 mL assay medium [containing 100mM KCl, 50mM MOPS, 5mM
KH2PO4, 5mM EGTA, 1mMMgCl2, 5 mM glutamate, and 5mMmalate]
and assayed for tert-butyl-induced pore opening in a fluorescence
spectrophotometer at 37 °C. Calcium uptake was taken from the fall in
extramitochondrial Ca2+ following a bolus injection of 3 μL of 15mM
Ca2+ (30 nmoles Ca2+/mg mitochondrial protein) and tert-butyl-in-
duced calcium release were assessed in both isolated subpopulations
SSM and IFM after calcium uptake. Tert-butyl hydrogen peroxide
(400mM) was infused at a rate of 0.2 μL/min, and the concentration of
free Ca2+ in the medium was calculated by monitoring the fluorescence
of the Ca2+ indicator calcium green-5N (CaGN-5N; Molecular Probes)
with an excitation and emission of 488 and 530, respectively. MPTP
opening was inferred from the sudden and large increase of fluores-
cence.
2.1.7. Swelling assay
Ca2+ tolerance was evaluated according to previous reports
[21,25,26]. Briefly, mitochondria were resuspended in swelling buffer
[containing 100mM KCl, 50mM MOPS, 5mM KH2PO4, 5 µM EGTA,
1mM MgCl2, 5 mM glutamate, and 5mM malate] at 2mg/mL protein
concentration and warmed to room temperature in a 96-well plate.
CaCl2 (100 and 500 nM/mg of mitochondrial protein) was added. The
time-dependent decrease in absorbance at 540 nm is indicative of the
tendency for MPTP opening and mitochondrial swelling.
2.1.8. Hydrogen peroxide production
Hydrogen peroxide production in isolated mitochondrial sub-
populations was determined using the oxidation of the fluorogenic in-
dicator Amplex Red (Invitrogen) in the presence of horseradish perox-
idase as previously described [21]. The concentrations of horseradish
peroxidase and Amplex Red in the incubation were 0.1 unit/mL and
50 μM, respectively, and detection of fluorescence was assessed on a on
a Molecular Devices Flex Station 3 fluorescence plate reader (Molecular
Devices, Sunnyvale, CA) with 530-nm excitation and 590-nm emission
wavelengths. Standard curves were obtained by adding known amounts
of H2O2 to the assay medium in the presence of the substrates amplex
red and horseradish peroxidase. H2O2 production was initiated in mi-
tochondria using glutamate + malate (G + M) and succinate + rote-
none (S + R) as substrates.
2.1.9. Enzyme activity
Citrate synthase, MCAD and aconitase activities were measured as
previously described [27]. For citrate synthase, briefly, 0.5 μL of myo-
cardial tissue homogenate was added to cuvettes containing 500 μL of
CS reaction mix (0.1M Tris-HCl, 1.25mM 5,5′-dithiobis [2-nitrobenzoic
acid], pH 8). Then, 25 μL of 50mM oxaloacetate and 5mM acetyl-CoA
were added to the reaction mixture, and the increase in absorbance at
412 nm was measured over 5min. Activity was then determined by
multiplying the slope to the molar concentration constant for 5,5′-di-
thiobis[2-nitrobenzoic acid] (13,600M−1).
For MCAD activity, 5 μL of myocardial tissue homogenate was
added to cuvettes containing 500 μL of 100mM KH2PO4, 1mM EDTA,
0.5 mM sodium tetrathionate, and 200 μM ferrocenium hexa-
fluorophosphate, pH 7.4. Then, 50 μL of 0.5 mM octanoyl-CoA was
added to the reaction mixture, and the decrease in absorbance at
300 nm was measured over 5min. Activity was then determined by
multiplying the slope to the molar concentration constant for ferroce-
nium hexafluorophosphate (4300M−1).
For aconitase activity, 10 μL of myocardial tissue homogenate was
added to cuvettes containing 490 μL of aconitase reaction mix (0.083%
chloroform, 1.67mM sodium citrate, 26.7 mM triethanolamine, 0.5mM
NADP+, .5mM MgCl2, pH 7.4), and the increase in absorbance at
340 nm was measured over 5min. Activity was then determined by
multiplying the slope to the molar concentration constant for NADPH
(6.7M−1).
3. Statistical analysis
Values are shown as mean± standard error of the mean (SEM)
unless otherwise specified. For comparisons between groups, we used
one or two-way analysis of variance (1 or 2-way ANOVA), and if sta-
tistically significant differences were detected, Fischer's post hoc test
was applied to further identify groups with different means. Differences
were considered significant for P values of less than 0.05.
4. Results
4.1. Development of heart failure in response to pressure overload
Heart Failure became manifest at 14 weeks following aortic con-
striction, as indicated by a 50% increase in LV mass, hypertrophy of the
atria and right ventricle, greater LV all thickness, significant increases
in LV end systolic and diastolic volumes and a decreased ejection
fraction. Furthermore, MitoQ decreased right ventricular hypertrophy
and lung congestion induced by pressure overload after 14 weeks.
Although TAC animals did not present ejection fraction below 30–40%
which is the main criteria for heart failure classification, the animals
present Lung/BW ≥ Lung/BWSham; + 2 SD (Lung wet weight; BW =
body weight; SD = standard deviation); RV hypertrophy was propor-
tional to Lung/BW (Tables 1 and 2) [26,28].
4.2. Mitochondrial yield, membrane potential and morphology
The heart failure group had a significant 23% decrease in IFM yield
and a 16% decrease in SSM yield that were not altered by MitoQ (mg of
mitochondrial protein extracted per gram of myocardium) (Fig. 1A).
Thus, the heart failure group had a lower total mitochondrial content in
myocardium. Further, we also measured mitochondrial membrane po-
tential by flow cytometry. For membrane potential, mitochondria were
incubated with 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazol
carbocyanine iodide (JC-1) at a final concentration of 0.3 μM. The shift
to orange is due to dye aggregates forming upon polarization, causing
shifts in emitted light from 530 nm (green) to 590 nm (orange). The
Table 1
MitoQ does not alter cardiac hypertrophy in the left ventricle induced by transverse aortic
constriction but improves hypertrophy in the right ventricle after 14 weeks of treatment.
Changes in body weight (BW), left ventricle to tibia length ratio (LV/tibia), right ventricle
weight to tibia length ratio (RV/tibia), atrial weight to tibia length ratio (AW/tibia), liver
weight, retroperitoneal + epididymal fat (% of total weight), lung (wet to dry ratio),
kidney, gastrocnemius, soleus in SHAM, TAC and TAC plus MitoQ. N - Number of animals
used. *p< .05 compared to SHAM. #p< .05 compared to TAC. Results are expressed as
the means± SEM. Differences were analyzed using one-way ANOVA followed by a post
hoc Fischer test.
SHAM (N = 13) TAC (N = 15) TAC MitoQ (N =
15)
Body weight (g) 414±8 390±6.7 403±6.9
LV/tibia (mg/mm) 22±0.42 33±0.76* 34± 1.2*
RV/tibia (mg/mm) 5±0.16 10.5±0.29* 8.9± 0.501*,#
AW/tibia (mg/mm) 1.6± 0.09 5.4± 0.33* 4.8± 0.33*
Liver (g) 12±0.23 13±0.27 13±0.33
Retroperitoneal +
epididymal fat (%
of total weight)
20±1.3 14±0.7* 15± 0.63*
Lung weight (g) 1.47± 0.05 5.23±0.18* 4.23± 0.44*,#
Data are means± SEM. LV/tibia, left ventricle-to-tibia ratio; RV/tibia, right ventricle-to-
tibia ratio; AW/tibia, atrial weigh-to-tibia ratio.
* P< .05 vs SHAM.
# P< .05 vs TAC. Differences were analyzed using one-way ANOVA followed by a post
hoc Fischer test.
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membrane potential was decreased in the IFM from the heart failure
group. Interestingly, MitoQ restored membrane potential in the IFM.
MitoQ also increased the membrane potential in the SSM, although the
membrane potential was not found reduced in the TAC group for this
subpopulation (Fig. 1B).
To assess mitochondrial morphology and internal complexity, the
arithmetic mean output from the forward scatter (FSC) detector was
used as an index of mitochondrial size and the arithmetic mean output
from the side scatter was used as an index of mitochondrial internal
complexity. Size and internal complexity were not altered in both
subpopulation in the heart failure group. However, MitoQ reduced size
and internal complexity in heart failure (Fig. 1C and D).
4.3. Mitochondrial respiration
To study the effect of heart failure on different functional compo-
nents of IFM and SSM, we measured mitochondrial respiration with
different substrates (palmitoylcarnitine, glutamate + malate, and suc-
cinate) that use distinct mitochondrial transport, oxidative pathways
and provide specific substrates to Complex I and Complex II. To assess
β-oxidation, we used palmitoylcarnitine that reflects mitochondrial
palmitoylcarnitine transport, palmitate oxidation, the activity of entire
ETC and the phosphorylation process. The combination of glutamate
and malate as substrate produces NADH, NADH donates electrons for
Complex I, thus allowing the study of the aspartate shuttle. Succinate is
oxidized in Complex II (bypassing Complex I) and the addition of ro-
tenone, an inhibitor of Complex I, allows assessing the activity of
complex II. The maximal rate of mitochondrial respiration (state 3) in
Table 2
MitoQ does not change echocardiography indices of transverse aortic constriction induced HF model in rats after 14 weeks of treatment. Changes in left ventricular end diastolic diameter,
left ventricular end systolic diameter, end diastolic anterior wall thickness, end diastolic posterior wall thickness, endocardial fractional area change (%), diastolic volume, systolic
volume, left ventricular fractional shortening and ejection fraction (%) in SHAM, TAC and TAC plus MitoQ. N - Number of animals used. *p< .05 compared to SHAM. Results are
expressed as the means± SEM. Differences were analyzed using one-way ANOVA followed by a post hoc Fischer test.
SHAM (N = 13) TAC (N = 15) TAC MitoQ (N = 15)
LV end diastolic diameter (mm) 7.7±0.17 8.4±0.22 8.3± 0.26
LV end systolic diameter (mm) 4.3±0.16 5.9±0.19* 5.7± 0.29
End diastolic anterior wall thickness (mm) 1.9±0.096 2.9±0.11* 3.1± 0.12*
End diastolic posterior wall thickness (mm) 2.1±0.14 2.7±0.11* 2.8± 0.15*
Endocardial Fractional Area Change (%) 64±2.5 42±2.3* 41±3.2*
Diastolic Volume (mL) 0.49± 0.033 0.64± 0.053* 0.62± 0.056*
Systolic Volume (mL) 0.089± 0.0092 0.23± 0.023* 0.22± 0.029*
LV fractional shortening 0.44± 0.016 0.29± 0.015* 0.31± 0.021*
Ejection Fraction (%) 82±1.4 64±2.3* 66±2.7*
Data are means± SEM.
* P< .05 vs SHAM. Differences were analyzed using one-way ANOVA followed by a post hoc Fischer test.
Fig. 1. MitoQ restores mitochondrial membrane potential, decreases size and internal complexity in subsarcolemmal mitochondria in heart failure after 14 weeks of
transverse aortic constriction. Changes in mitochondrial yield, membrane potential, size and internal complexity in SHAM, TAC and TAC plus MitoQ. N - Number of animals used.
*p< .05 compared to SHAM. #p< .05 compared to TAC. Results are expressed as the means± SEM. Differences were analyzed using one-way ANOVA followed by a post hoc Fischer
test. (For interpretation of the references to color in this figure, the reader is referred to the web version of this article.)
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isolated mitochondria expressed per mg of mitochondrial protein was
decreased by 20% in IFM and 16% in SSM from heart failure animals
with glutamate + malate as substrates, furthermore, MitoQ restored
mitochondrial respiration (state 3) in both subpopulations (Fig. 2A and
2B). We also detected an increase in state 4 in IFM from heart failure
rats with glutamate + malate as substrates. Although MitoQ did not
reduce the increase in state 4 in IFM from heart failure animals, there
was a tendency to be statistically significant (P = .07) (Fig. 2C). On the
other hand, state 4 was not different in SSM but there was a tendency to
be increased in heart failure animals (P = .05). In addition, heart
failure animals treated with MitoQ showed similar values for state 4
when compared to the SHAM group (Fig. 2D).
The respiratory control ratio (state 3/state 4), an index of the ability
of mitochondria to increase ATP generation above basal values in
Fig. 2. MitoQ restores mitochondrial dysfunction in IFM and SSM in heart failure induced by pressure overload after 14 weeks of transverse aortic constriction. Mitochondrial
subpopulations respiration. Individual mitochondrial subpopulations were isolated from SHAM, TAC and TAC plus MitoQ hearts, and polarographic measurements were performed to
index oxygen consumption under state 3 and 4 respiration conditions. Respiration of individual electron transport chain (ETC) complex was defined as the rate of oxygen consumed in the
presence of specific substrate (glutamate and malate) for complex I. All respiration rates are expressed in Atoms O.mg mitochondrial protein-1 min−1. RCR (respiratory control ratio, state
3/state 4) and the ratio of ADP:O in isolated subsarcolemmal and Intermyofibrillar mitochondria. Number of animals used 13–15 per group. *p< .05 compared to SHAM. #p< .05
compared to TAC. Results are expressed as the means± SEM. Differences were analyzed using one-way ANOVA followed by a post hoc Fischer test.
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response to maximally stimulating conditions, was decreased in IFM but
not SSM in heart failure when glutamate + malate as substrates. MitoQ
restored the decrease in RCR in IFM (Fig. 2E) and, although the RCR in
SSM from heart failure animals was not decreased, heart failures
animals treated with MitoQ showed higher values when compared to
the heart failure group (Fig. 2F). ADP/O ratio was also found decreased
in IFM and SSM from heart failure animals. In addition, MitoQ restored
the ADP/O ration in SSM but not in IFM (Figs. 2G and 2H).
Fig. 3. MitoQ restores β-oxidation in subsarcolemmal mitochondria from heart failure induced by pressure overload after 14 weeks of transverse aortic constriction.
Mitochondrial subpopulations respiration. Individual mitochondrial subpopulations were isolated from SHAM, TAC and TAC plus MitoQ hearts, and polarographic measurements were
performed to index oxygen consumption under state 3 and 4 respiration conditions. Respiration of individual electron transport chain (ETC) complex was defined as the rate of oxygen
consumed in the presence of specific substrate (Palmitoyl-carnitine) for β-oxidation. All respiration rates are expressed in Atoms O.mg mitochondrial protein-1 min−1, RCR (respiratory
control ratio, state 3/state 4) and the ratio of ADP:O in isolated subsarcolemmal and Intermyofibrillar mitochondria. Number of animals used 13–15 per group. *p< .05 compared to
SHAM. #p< .05 compared to TAC. Results are expressed as the means± SEM. Differences were analyzed using one-way ANOVA followed by a post hoc Fischer test.
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We next aimed to analyze β-oxidation and to doing that, we used
palmitoylcarnitine, which reflects mitochondrial palmitoylcarnitine
transport and palmitate oxidation. As expected, the maximal rate of
mitochondrial respiration (state 3) in isolated mitochondria expressed
per mg of mitochondrial protein was decreased in SSM but not IFM
from heart failure rats. MitoQ restored this decrease found in heart
failure animals (Fig. 3A and B). We also detected higher values for state
4 in IFM but not SSM from heart failure animals when
Fig. 4. MitoQ restores the increase in state 4 in intermyofibrillar mitochondria from heart failure induced by pressure overload after 14 weeks of transverse aortic con-
striction. Mitochondrial subpopulations respiration. Individual mitochondrial subpopulations were isolated from SHAM, TAC and TAC plus MitoQ hearts, and polarographic mea-
surements were performed to index oxygen consumption under state 3 and 4 respiration conditions. Respiration of individual electron transport chain (ETC) complex was defined as the
rate of oxygen consumed in the presence of specific substrate (succinate + rotenone) for complex II. All respiration rates are expressed in Atoms O.mg mitochondrial protein-1 min−1,
RCR (respiratory control ratio, state 3/state 4) and the ratio of ADP:O in isolated subsarcolemmal and Intermyofibrillar mitochondria. Number of animals used 13–15 per group. *p< .05
compared to SHAM. #p< .05 compared to TAC. Results are expressed as the means± SEM. Differences were analyzed using one-way ANOVA followed by a post hoc Fischer test.
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palmitoylcarnitine was used as substrate. Furthermore, MitoQ restored
the increase in state 4 in IFM from heart failure animals (Fig. 3C and D).
The respiratory control ratio (state 3/state 4) was reduced in IFM
and SSM from heart failure animals, although there was a tendency to
be statistically significant only in IFM (P = .05). Interestingly, heart
failure animals treated with MitoQ showed similar values compared to
the SHAM group (Fig. 3E and F). The ADP/O ratio not different among
groups when palmitoylcarnitine was used as substrate (Fig. 3G and H).
Finally, we inhibited complex I with rotenone and provided sub-
strate for complex II (succinate). Heart failure did not affect state 3 with
succinate as substrate in both subpopulations (Fig. 4A and B). Fur-
thermore, state 4 was found increased in the IFM but not in SSM
(Fig. 4C and D). We also analyzed RCR and ADP:O ratio in both sub-
populations and we found a modest decrease in the ADP:O ratio in IFM
but not SSM (Fig. 4E, F, G and H).
Taken together, heart failure resulted in loss of mitochondrial con-
tent and tissue respiratory capacity in both subpopulations and MitoQ
was able to improve respiratory capacity.
4.4. Effects of heart failure on biochemical parameters
Heart failure decreases the capacity for oxidative metabolism in
myocardium, as reflected in a decrease in the activities of citrate syn-
thase, aconitase and medium-chain acyl-CoA dehydrogenase (MCAD).
The activities of these enzymes were decreased by pressure overload-
induced heart failure and were not affected by MitoQ treatment
(Fig. 5A, B and C).
We also measured the activities of these enzymes in both sub-
populations separately and we found that citrate synthase and MCAD
were decreased by heart failure-induced by pressure overload in IFM
and SSM (Fig. 5D, E, G and H) whereas aconitase as not altered by hear
failure in the isolated mitochondria (Fig. 5F and I). Furthermore, MitoQ
did not alter the decrease in mitochondrial enzyme activity, however,
aconitase activity in the SSM was found increased in heart failure group
treated with MitoQ (Fig. 5I).
4.5. Hydrogen peroxide production
The capacity for mitochondrial generation of H2O2 was assessed in
IFM and SSM from LV myocardium using the amplex red assay. Heart
Fig. 5. Heart failure decreases myocardial activity of mitochondrial function and the fatty acid oxidation pathway. Myocardial activity of citrate synthase (CS), medium chain
acyl-CoA dehydrogenase (MCAD) (B) and aconitase (C). Activity of citrate synthase (CS) (D), medium chain acyl-CoA dehydrogenase (MCAD) (E) and aconitase (F) in the intermyofibrillar
mitochondria. Activity of citrate synthase (CS) (G), medium chain acyl-CoA dehydrogenase (MCAD) (H) and aconitase (I) in the subsarcolemmal mitochondria. Individual mitochondrial
subpopulations were isolated from SHAM, TAC and TAC plus MitoQ hearts. Number of animals used 13–15 per group. *p< .05 compared to SHAM. #p< .05 compared to TAC. Results
are expressed as the means± SEM. Differences were analyzed using one-way ANOVA followed by a post hoc Fischer test.
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failure significantly increased mitochondrial generation of H2O2 in both
subpopulations, IFM and SSM with either glutamate + malate or suc-
cinate in the presence of the rotenone to inhibit complex I. As expected,
MitoQ normalized hydrogen peroxide production in heart failure-in-
duced by pressure overload (Fig. 6A, B, C and D).
4.6. Permeability transition
Two established methods were used to assess Ca2+-induced MPT in
LV mitochondria. First, it was assessed from the measurement of the
ability of isolated mitochondria to take up added Ca2+. A small amount
of calcium was added to the medium (30 nmoles Ca2+/mg mitochon-
drial protein) and the fluorescence was measured over 5min. After
stabilization, tert-butyl hydrogen peroxide (400mM) was infused at a
rate of 0.2 μL/min, and the concentration of free Ca2+ in the medium
was calculated by monitoring the fluorescence of the Ca2+ indicator
calcium green-5N. Heart failure decreased the ability of IFM to take up
calcium whereas SSM did not show any difference among groups.
MitoQ was able to improve the maximal rate of mitochondrial calcium
uptake in IFM (Fig. 7A).
There was a significantly greater sensitivity to tert-butyl hydrogen
peroxide-induced MPT in IFM and SSM in heart failure group as re-
flected by a higher extramitochondrial [Ca2+] for a given cumulative
load of tert-butyl hydrogen peroxide. MitoQ was able to improve tert-
butyl hydrogen peroxide-induced MPT in IFM and SSM (Fig. 7C and D).
Second, MPT was assessed from mitochondrial swelling induced by
high [Ca2+] as reflected by the decrease in absorbance at 540 nm
following the addition of a bolus of Ca2+ to isolated mitochondria.
There was a decrease in absorbance with addition of either 100 or
500 nmol Ca2+/mg protein in all groups, with a greater decline in IFM
and SSM from heart failure-induced by pressure overload. MitoQ
treatment improved the ability of isolated mitochondria to swell in IFM
and SSM with addition of either 100 or 500 nmol Ca2+/mg (Fig. 8A, B,
C and D).
5. Discussion
This study was designed to assess the effect of MitoQ on pressure
overload-induced heart failure in two diverse mitochondrial popula-
tions, IFM and SSM, characterized with distinct biochemical properties
and functions. The main findings are that pressure overload-induced
heart failure in rats decreased cardiac function in vivo that was not al-
tered by MitoQ. However, we observed a slight improvement in RV
hypertrophy in heart failure animals treated with MitoQ for 14 weeks.
Heart failure also decreased total mitochondrial protein content, mi-
tochondrial membrane potential in the intermyofibrillar mitochondria.
MitoQ restored membrane potential in IFM but did not alter mi-
tochondrial protein content. These alterations are associated with the
impairment of basal and stimulated mitochondrial respiration in IFM
and SSM induced by heart failure. Moreover, MitoQ restored mi-
tochondrial respiration in heart failure induced by pressure overload.
We also detected higher levels of hydrogen peroxide production in
heart failure and MitoQ restored the increase in ROS production after
14 weeks. MitoQ was also able to increase mitochondrial calcium
Fig. 6. MitoQ restores hydrogen peroxide production in intermyofibrillar and subsarcolemmal mitochondria from heart failure induced by pressure overload after 14 weeks
of transverse aortic constriction. Hydrogen peroxide production in intermyofibrillar and subsarcolemmal mitochondria from individual mitochondrial subpopulations isolated from
SHAM, TAC and TAC plus MitoQ hearts. Two different substrates were used to assess hydrogen peroxide production from complex I (glutamate + malate) and complex III (rotenone +
succinate). Number of animals used is indicated in parenthesis. *p< .05 compared to SHAM. #p< .05 compared to TAC. Results are expressed as the means± SEM. Differences were
analyzed using two-way ANOVA followed by a post hoc Fischer test.
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retention capacity.
Epidemiological studies show that cardiac hypertrophy is a strong
predictor for the development of heart failure and it has been postu-
lated that the reduction in oxidative phosphorylation accelerates the
decline during the transition from left ventricular hypertrophy to heart
failure as mentioned in the introduction.
Heart failure induced by pressure overload differently affects the
two distinct mitochondrial subpopulations. As described in the litera-
ture, IFM is smaller and shows reduced internal complexity than SSM.
Our data also shows higher respiratory capacity in IFM than in SSM.
Heart failure after 14 weeks decreased mitochondrial respiratory ca-
pacity, thus our findings are consistent with previous results [29,30].
This information is relevant because differences between IFM and SSM
are often not addressed in recent publications, these two distinct sub-
populations respond to pathological conditions in a heterogeneous
fashion, such as diabetes [31], in cardiomyopathic hamsters [32] and
heart failure [33,34]. Additionally, we describe for the first time that
MitoQ restored mitochondrial stimulated and limited respiration after
14 weeks in heart failure. This result corroborates previous findings
showing that mice pre-treated with MitoQ had enhanced recovery after
ischemia/reperfusion injury, demonstrating that MitoQ inhibited ac-
cumulation of reactive oxygen species and apoptosis induction [35].
It is well known that the failing heart has reduced capacity for
oxidizing fatty acid as fuel. Down regulation of fatty acid oxidation
gene expression is a well-characterized response in the hypertrophied
myocardium driven, at least in part, by reduced PPAR alpha [5,36–39],
which is responsible for transcriptional control of genes involved in
fatty acid utilization [40]. To confirm this hypothesis, we used palmi-
toylcarnitine to evaluate palmitate transport and oxidation. Our find-
ings show that β-oxidation is reduced in heart failure due to a decrease
in state 3 respiration with palmitoylcarnitine as substrate in the SSM.
Interestingly, MitoQ restored stimulated respiration with this substrate.
We also demonstrated that respiratory control ratio is decreased in
heart failure. Mitochondrial respiratory control ratio encapsulates the
main function of mitochondria, which is the ability to idle at a low rate
yet respond to ADP by making ATP at a high rate. Moreover, MitoQ
normalized RCR values when compared to the heart failure group.
To confirm this result, MCAD activity was found decreased in the
LV, IFM and SSM in heart failure, although MitoQ did not restore the
activity of this enzyme, the activity of MCAD in SSM from heart failure
group treated with MitoQ was not reduced as compared to SHAM.
These results suggest that MitoQ could be useful to prevent the sub-
strate shift found in heart failure. It has been shown that overexpression
of mitochondrial catalase attenuates pressure overload-induced heart
failure, demonstrating that scavenging mitochondrial ROS preserves
the fatty acid oxidation pathway in heart failure [41].
Mitochondria has been designated as the main source of reactive
oxygen species within the cardiomyocyte. Excessive ROS production
from mitochondria has been described in heart failure [42,43], leading
to permeability and irreversible injury of the mitochondria [44].
Fig. 7. Calcium-uptake capacity and reactive oxygen species (ROS) sensitivity of mitochondria isolated from SHAM, TAC and TAC plus MitoQ hearts. A: rate of Ca2+ uptake by
interfibrillar mitochondria (IFM) is monitored as a decrease in fluorescence of the extra-mitochondrial Ca2+ indicator (CaGN-5N; 700 nM). B: decrease in CaGN-5N fluorescence over time
due to the uptake of Ca2+ by subsarcolemmal mitochondria (SSM). C: IFM mitochondria were primed for mitochondrial permeability transition pore (MPTP) opening with a low
concentration of Ca2+ (22.5 µM) and were subsequently exposed to increasingly higher doses of tBH. Mitochondrial Ca2+ release as a result of tBH-induced MPTP was monitored as an
increase in CaGN-5N fluorescence. D: increase in CaGN-5N fluorescence due to tBH-induced MPTP opening in SSM. AU, arbitrary fluorescence units; tBH, tert-butyl-hydroxyperoxide.).
Number of animals used is indicated in parenthesis. *p< .05 compared to SHAM. #p< .05 compared to TAC. Results are expressed as the means± SEM. Differences were analyzed using
two-way ANOVA followed by a post hoc Fischer test.
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Considering these data, direct targeting mitochondrial ROS by agents
which accumulate in mitochondria such as MitoQ, have emerged as
promising agents. MitoQ is oxidized by ROS and is reduced by electrons
from complex II [45,46]. Our data shows that mitochondrial hydrogen
peroxide was normalized by MitoQ treatment after 14 weeks, demon-
strating that MitoQ was efficient in reducing mitochondrial ROS pro-
duction in heart failure.
ROS and calcium also favor permeability transition pore opening in
mitochondria. ROS, including H2O2 can greatly sensitize the mPTP to
Ca2+ and triggers mitochondrial permeability transition [47]. Our data
shows that MitoQ decreased mitochondrial permeability in a greater
extension in SSM but we observed a slight change in IFM, demon-
strating that decreasing mitochondrial ROS production can reduce
mPTP formation. We cannot rule out the possibility that MitoQ is ef-
fective in SSM due to its location within the cell. The limitations of the
present investigation needs to be addressed. MitoQ did not alter LV
hypertrophy or function in vivo, however, we observed a decrease in RV
and lung weight as compared to the sham group, demonstrating that
MitoQ had some significant effect on these organs. Regarding ven-
tricular function, it is very well known that its function depends on
preload, afterload and heart rate. In this in vivo model with changes in
diastolic volume and severe hypertrophy, it is not adequate to conclude
that MitoQ had no beneficial effects on ventricular function. Further
experiments such as using isolated heart will be necessary to investigate
whether MitoQ affects ventricular function. Furthermore, in TAC
models, collagen deposition and fibrosis is present and we cannot rule
out that MitoQ might decrease collagen deposition in this model but
further experiments will be necessary to address this issue.
The difference that was not found in the LV could be attributed to
the small concentration used in drinking water (100 µM). To confirm
this hypothesis, a higher concentration must be used to treat HF ani-
mals.
6. Conclusion
In summary, MitoQ improves mitochondrial dysfunction in heart
failure induced by pressure overload, by decreasing hydrogen peroxide
formation, improving mitochondrial respiration and improving mPTP
formation.
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